Molecular Mechanisms by Which a Fucus vesiculosus Extract Mediates Cell Cycle Inhibition and Cell Death in Pancreatic Cancer Cells.

Ulf Geisen, Marion Zenthoefer, Matthias Peipp, Jannik Kerber, Johannes Plenge, Antonella Managò, Markus Fuhrmann, Roland Geyer, Steffen Hennig, Dieter Adam, Levent Piker, Gerald Rimbach, Holger Kalthoff

Journal: Marine drugs 2016;13(7):4470-91

PMID: 26204945

Abstract

Pancreatic cancer is one of the most aggressive cancer entities, with an extremely poor 5-year survival rate. Therefore, novel therapeutic agents with specific modes of action are urgently needed. Marine organisms represent a promising source to identify new pharmacologically active substances. Secondary metabolites derived from marine algae are of particular interest. The present work describes cellular and molecular mechanisms induced by an HPLC-fractionated, hydrophilic extract derived from the Baltic brown seaweed Fucus vesiculosus (Fv1). Treatment with Fv1 resulted in a strong inhibition of viability in various pancreatic cancer cell lines. This extract inhibited the cell cycle of proliferating cells due to the up-regulation of cell cycle inhibitors, shown on the mRNA (microarray data) and protein level. As a result, cells were dying in a caspase-independent manner. Experiments with non-dividing cells showed that proliferation is a prerequisite for the effectiveness of Fv1. Importantly, Fv1 showed low cytotoxic activity against non-malignant resting T cells and terminally differentiated cells like erythrocytes. Interestingly, accelerated killing effects were observed in combination with inhibitors of autophagy. Our in vitro data suggest that Fv1 may represent a promising new agent that deserves further development towards clinical application.

Address: Division of Molecular Oncology, Institute for Experimental Cancer Research, Medical Faculty, CAU, University Hospital Schleswig-Holstein, 24105 Kiel, Germany. [email protected].; CRM, Coastal Research & Management, 24159 Kiel, Germany. [email protected].; Division of Stem Cell Transplantation and Immunotherapy, Department of Internal Medicine II, University Hospital Schleswig-Holstein, 24105 Kiel, Germany. [email protected].; Division of Molecular Oncology, Institute for Experimental Cancer Research, Medical Faculty, CAU, University Hospital Schleswig-Holstein, 24105 Kiel, Germany. [email protected].; Institute of Immunology, University Hospital Schleswig-Holstein, 24105 Kiel, Germany. [email protected].; Department of Biology, University of Padua, 35131 Padua, Italy. [email protected].; Numares AG, 93053 Regensburg, Germany. [email protected].; Numares AG, 93053 Regensburg, Germany. [email protected].; CRM, Coastal Research & Management, 24159 Kiel, Germany. [email protected].; Institute of Immunology, University Hospital Schleswig-Holstein, 24105 Kiel, Germany. [email protected].; CRM, Coastal Research & Management, 24159 Kiel, Germany. [email protected].; Institute of Human Nutrition and Food Science, Christian-Albrechts University of Kiel, 24118 Kiel, Germany. [email protected].; Division of Molecular Oncology, Institute for Experimental Cancer Research, Medical Faculty, CAU, University Hospital Schleswig-Holstein, 24105 Kiel, Germany. [email protected].
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.